Opiant Pharmaceuticals, Inc. (OPNT)

Market Cap	108.80M
Revenue (ttm)	22.34M
Net Income (ttm)	-33.09M
Shares Out	5.27M
EPS (ttm)	-6.57
PE Ratio	n/a
Forward PE	26.74
Dividend	n/a
Ex-Dividend Date	n/a

Volume	492,256
Open	20.88
Previous Close	20.65
Day's Range	20.50 - 21.00
52-Week Range	7.34 - 29.25
Beta	0.83
Analysts	Sell
Price Target	21.93 (+6.2%)
Earnings Date	Mar 21, 2023

About OPNT

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorpo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 37
• Stock Exchange: NASDAQ
• Ticker Symbol: OPNT

Analyst Forecast

According to 7 analysts, the average rating for OPNT stock is "Sell." The 12-month stock price forecast is $21.93, which is an increase of 6.20% from the latest price.

Price Target

$21.93

(6.20% upside)

Analyst Consensus: Sell